
The 4th Medium Term Management Plan FY Feb. 2010 - FY Feb. 2014

This presentation material contains information that constitutes forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors including changes in material circumstances.

> Hisamitsu Pharmaceutical Co., Inc. July 27, 2009

> > Patch and Care of People around the World





2) Obtaining competitive edge outside Japan

3) Strengthening TDDS R&D

Patch and Care of People around the World

1) Strengthen differences in products and sales activities

Continued improvements which fit customers' needs

Ethical Pharmaceutical

Increase of MRs, building a sales structure which realizes sufficient calls for existing / new products.

> Target JPY97 billion; total of Mohrus and Mohrus Tape (Share > 54% in 2nd generation NSAID patches)
> Target > JPY20 billion; Total

of HFT-290 and BTDS


<u>OTC</u>

Addition of items, continued launch of new products

Expand current top shares in external analgesic antiinflammatory patches (share > 40%) and athlete foot products (share > 30%)

Continued enhancement of added-value and brands of domestic business 3

Ethical Pharmaceutical - Sales Target (Domestic)



OTC Sales Target (Domestic)

CAGR(+3.3%)30,000 JPY million 25,500 1,000 25,000 21,947 21,688 21,700 3,000 New Products Butenalock 100 2558 2606 3.000 20,000 🗆 Salonsip 3050 Feitas 3804 3574 6,000 Salonpas 15,000 Other Products 5,200 ,042 4,39 6,000 10,000 5,200 5,535 5,414 5,000 n FY Feb 2014E FY Feb 2008 FY Feb 2010E FY Feb 2009

CAGR(+6.6%)

Aisamitsu



7

Aisamitsu

Overview of Noven Pharmaceuticals

Overview			Sales and net profits (US\$ million)						
 Headquarters: Established: Sales (FY2008): Net Profit (FY2008): Stock Listing: Market Cap (as of Jul. 13, 2) Number of employees (as of solution) 		Sales \$125 - 100 - 75 - 50 - 25 - 0 - *	\$60.7 FY2006	8 = 33.5% 883.2 FY2007	\$108.2 FY2008	\$25 0 -25 -50	FY2006 e to JDS	(\$45.4) FY2007* Pharmace	\$21.4 FY2008 euticals

Patch and Care of People around the World

Products on the Market

Products⁽¹⁾ Indication **Mode of action Noven Therapeutics** Depression, Panic Selective Serotonin Reuptake Inhibitor (SSRI) **Pexeva**[®] Disorder, OCD, (paroxetine mesylate) GAD Bipolar disorder **GSK-3** β inihibitor (Lithium Carbonate, USP) Bipolar disorder, **∛Stavzor** GABA-T inhibitor (valproic acid delayed release capsules) Migraine, Seizures Noven Transdermals Menopausal syndrome,
 Estradiol transdermal system VIVELLEdol Osteoporosis Menopausal syndrome,
 Estradiol/norethindrone acetate transdermal system Combi patch Daytrana" (■ Norepinephrine and dopamine reuptake inhibitor ADHD


(1) DentiPatch (topical anesthesia prior to superficial dental procedures) is sold by several independent marketers.

disamitsu

Product Pipelines

Product	Comments						
Noven Therapeutics							
Mesafem	 Indication: Vasomotor symptoms (VMS) associated with menopause Oral formulation of low-dose paroxetine mesylate Uncertain, and promising pipeline product targeting 23 million VMS patients in US Current stage: Phase 2 Launch: Expecting approximately 2H 2011 Non-hormonal product, Mode of action: GABA-T inhibitor 						
Noven Transdermals							
Amphetamine Patch	 Indication: ADHD Pre-clinical Mode of action: Norepinephrine and dopamine reuptake inhibitor 						
Testosterone Patch	 Indication: Hypoactive Sexual Desire Disorder (HSDD) in post-menopausal women Partnered with P&G Pharmaceuticals Product: Low-dose testosterone patch 						

Patch and Care of People around the World



9

Aisamitsu

2) Obtaining Competitive Edge outside Japan

Improve the presence of Hisamitsu Pharmaceutical in countries of foreign operations.

Asia

Entry to new countries such as China

New products to existing countries and continued advertising investment

➢Building up sales infrastructure and bases in each country

≻Lowering cost of goods with utilizing manufacturing subsidiary in Asian countries

U.S.A.

➢Planning and performing sales strategy of FDA approved products.


✓ HFG-512, HKT-500

➤To strengthen distribution to chain stores and marketing of 'Salonpas Pain Relief Patch' and 'Salonpas Arthritis Pain'

Building up business infrastructure and to realize 15% of overseas sales

Patch and Care of People around the World

Med-Term Overseas Sales



11

disamitsu

- Integration of know-how of clinical development in Japan and US to result in shortening development period
- Integration of TDDS formulation technologies to realize a number of new TDDS formulations


Skill up of clinical development and realizing new TDDS formulations

Patch and Care of People around the World

R&D Pipeline – Med-Term Forecast

	Code	Formulation	1Q, 2009	FY2010E	FY2011E	FY2012E	FY2013E
JP	HFT-290	TDDS	Filed	Approved			
	BTDS	TDDS	Filed	Approved			
	KPT-220	TDDS	Filed	Approved			
	HTU-520	TDDS	ΡI				PIII Completed
	HOB-294	TDDS	ΡI				PIII Completed
	HFG-512	TDDS	Filed	Non-disclosed			
	HKT-500	TDDS	РШ			Approved	
	Mesafem (Noven)	Oral	ΡI		Approved		
US	Amphetamine (Noven)	TDDS	Pre-clinical				-
	Testosterone (Noven + P&G)	TDDS	On-hold				-
	Non-disclose		Up to P I				РШCompleted 1 РШ 1 РП 3

Target of the 4th Med-Term Management Plan



Profit/Loss in the 4th Med-Term Management Plan

- FY Feb 2014 Sales: JPY190 billion Operating profit: JPY43.5 billion
 - Compatible growth of consolidated sales and conservation of profit rates (Sales, Average annual growth rate: +8%)

Consolidated	2007.2	2008.2	2009.2	2010.2E 1st yr of Med-Term		2014.2E 5th yr of Med- Term
Net Revenue	109,791	119,061	124,656	128,600		190,000
Operating Profit	26,134	29,071	32,532	32,800		43,500
Ordinary Profit	27,001	30,204	32,477	33,100		48,300
Net income	15,847	18,663	19,120	19,800		29,000
(Profit/Share ¥)	178.74	210.45	215.63	225.84		330.74
Rate of RD Cost	8.5%	9.4%	7.7%	6.7%		10.0%
Rate of Overseas Sales	5.4%	5.7%	5.9%	6.5%		15.0%
% of operating profit	23.8%	24.4%	26.1%	25.5%		22.9%
% of ordinary profit	24.6%	25.4%	26.1%	25.7%	,	25.4%
% of net income	14.4%	15.7%	15.3%	15.4%		15.3%

<Actual and Targets in Med-Term*>

* Costs for integration such as cost for purchase, amortization of goodwill, in-process R&D cost are not included in Med-Term Profit/Loss target.

* Noven has not disclosed Med-Term Plan through to year 2013. Analysts' forecasts on Noven's profit/loss are being used.


Dividend Policy and Equity Policy

≻Basic Policy

> To realize long-term stable dividend considering future strategic investment policy

>To perform flexible share buyback according to conditions such as share price >Target

>Consolidated dividend ratio Maintaining >=30% (FY Feb 2014 E ¥100/share*)
>Consolidated ROE Maintaining >=15%



Patch and Care of People around the World

Aisamitsu

"Improving Quality of Life (QOL) for People in the World"

The 4th Med-Term Management Plan

July 27, 2009

Hisamitsu Pharmaceutical Co., Inc.